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ABSTRACT 47 
 48 
Transport of macromolecules through the nuclear pore by importins and exportins plays a critical 49 
role in the spatial regulation of protein activity. How cancer cells co-opt this process to promote 50 
tumorigenesis remains unclear. The epidermal growth factor receptor (EGFR) plays a critical 51 
role in normal development and in human cancer. Here we describe a mechanism of EGFR 52 
regulation through the importin β family member RAN Binding Protein 6 (RanBP6), a protein of 53 
hitherto unknown functions. We show that RanBP6 silencing impairs nuclear translocation of 54 
Signal transducer and activator of transcription 3 (STAT3), reduces STAT3 binding to the EGFR 55 
promoter, results in transcriptional derepression of EGFR, and increased EGFR pathway output. 56 
Focal deletions of the RanBP6 locus on chromosome 9p were found in a subset of glioblastoma 57 
(GBM) and silencing of RanBP6 promoted glioma growth in-vivo. Our results provide an 58 
example of EGFR deregulation in cancer through silencing of components of the nuclear import 59 
pathway. 60 
 61 
  62 
 3 
 
INTRODUCTION 63 
 64 
The epidermal growth factor receptor (EGFR) is a transmembrane receptor of the ErbB tyrosine 65 
kinase family that plays a central role in cell differentiation, proliferation and survival 1. EGFR 66 
binding to its ligands, for example the epidermal growth factor (EGF), leads to phosphorylation 67 
and dimerization of the receptor, recruitment of proteins containing Src homology 2 (SH2) and 68 
phosphotyrosine binding (PTB) domains, and activation of multiple downstream signaling 69 
pathways, including the mitogen-activated protein kinase (MAPK) pathway, the 70 
phosphatidylinositol 3-kinase (PI3K) pathway, and the phospholipase C–γ (PLC-γ) pathway. 71 
Activation of EGFR is followed by a series of molecular events that contain EGFR signal 72 
strength and duration. These events include endocytosis of the ligand-bound receptor, 73 
ubiquitination and lysosomal degradation of the receptor-ligand complex, and dephosphorylation 74 
of the receptor protein by protein tyrosine phosphatases 2.  75 
 76 
Recent studies have challenged the traditional view of EGFR regulation. Structural studies have 77 
characterized a distinctive "receptor-mediated" dimerization mechanism and identified allosteric 78 
changes that govern the regulation of the intracellular kinase domain 3. The study of EGFR and 79 
its coreceptors at the systems level identified additional EGFR binding partners, dynamic 80 
patterns of pathway activation, and further layers of EGFR regulation through feedback 81 
inhibitors and intracellular signal compartmentalization 4–6. Together, these findings highlight the 82 
need for a deeper understanding of EGFR regulation through other signaling pathways.  83 
 84 
To identify further mechanisms of EGFR regulation, we characterized the EGFR “interactome” 85 
through EGFR-immunoaffinity purification and identified Ran-Binding Protein 6 (RanBP6) as 86 
EGFR-associated protein. RanBP6 silencing resulted in increased EGFR RNA and protein levels 87 
and augmented EGFR pathway activation in response to EGF. Focal and broad deletions 88 
including the RanBP6 gene locus were identified in glioblastoma and RanBP6 silencing 89 
accelerated glioma growth in-vivo. Taken together, these findings suggest that RanBP6 serves as 90 
EGFR regulator that is disrupted in human cancer.  91 
 92 
RESULTS 93 
 94 
RanBP6 interacts with EGFR and Ran-GTPase pathway members 95 
To further advance our understanding of EGFR regulation, we immunoprecipitated endogenous 96 
EGFR from whole cell extracts of A431 human cancer cells, which had been serum starved over-97 
night and then stimulated for 5 minutes with EGF, and subjected trypsin digests of EGFR 98 
associated proteins to Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS). We 99 
identified 431 EGFR-associated proteins in three independent biological replicates. This list of 100 
proteins (Supplementary Data 1) comprised the majority of proteins (117/183) detected in a prior 101 
examination of the EGFR-interactome in A431 cells 7. About 40% of the proteins (175/431) 102 
associating with EGFR were listed as EGFR interactors in the Biological General Repository for 103 
Interaction Datasets (BioGRID) and represented well-characterized members of the canonical 104 
EGFR pathway, including components of the adaptor protein complex 2 (AP-2), members of the 105 
CBL family of E3 ubiquitin-protein ligases, Growth factor receptor-bound protein 2 (GRB2), 106 
SHC-transforming protein 1 (SHC1), Son of sevenless homolog 1 (SOS1), the 107 
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit α and β isoforms (PIK3CA and 108 
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PIK3CB, respectively), Phosphatidylinositol 3-kinase regulatory subunit α (PIK3R1), 1-109 
phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLCG1), and ERBB 110 
receptor feedback inhibitor 1 (ERRFI; also known as Mitogen-inducible gene 6 protein).  111 
 112 
In addition to these proteins with well-documented roles in EGFR signaling, gene ontology 113 
analysis (www.geneontology.org) showed an enrichment of proteins involved in protein import 114 
into nucleus (Fig. 1a and Supplementary Data 2). The most highly enriched pathway (GO: 115 
0006610) included Importin subunit β-1, Importin-5, Transportin-2, Importin-4, 60S ribosomal 116 
protein L23, Transportin-1, and Ran-binding protein 6. Within this group of proteins, only Ran 117 
Binding Protein 6 (RanBP6) had not previously been reported to bind to EGFR or functionally 118 
characterized. We therefore selected it for further study. RanBP6 was identified through eight 119 
different unique peptides (Fig. 1b). We cloned a doxycycline (Dox)-inducible RanBP6-V5 120 
tagged cDNA construct and expressed it in A431 cells. Immunoprecipitation with an antibody 121 
directed against the V5 epitope confirmed the interaction between RanBP6 and EGFR (Fig. 1c). 122 
We also examined the interaction between RanBP6 and EGFR in cells that do not overexpress 123 
EGFR. In both (HEK)-293T and LN18 glioblastoma cells, immuno-precipitation of endogenous 124 
EGFR pulled down RanBP6 (Supplementary Fig. 1). 125 
 126 
RanBP6 contains a putative Importin N-terminal domain (Imp. N-ter) (Fig. 1d), suggesting that it 127 
is a member of the importin β superfamily 8. By sequence similarity with RanBP5, which 128 
mediates nuclear import of ribosomal proteins 9, RanBP6 also contains several HEAT (= 129 
huntingtin, elongation factor 3, the PR65/A subunit of protein phosphatase 2A, and the lipid 130 
kinase Tor) repeats and a putative Ran Binding Domain (RBD). Sequence alignment of the 131 
putative RBDs of RanBP6, RanBP5 and importin β1 showed a high sequence homology across 132 
different species (Supplementary Fig. 2). We therefore examined interactions of RanBP6 with 133 
other members of the Ran-GTPase pathway. Classic nuclear shuttling is mediated by an 134 
importin-α·β complex where importin α recognizes a cargo protein containing a nuclear 135 
localization signal (NLS) and these two proteins then form a ternary complex with importin β1. 136 
The ternary complex is dissociated in the nucleus and cargo protein released after binding of 137 
importin β1 to nuclear Ran-GTP 10. Importin-β and β-like importins can mediate nuclear 138 
translocation without the assistance of importin-α 11,12. We therefore examined the association of 139 
RanBP6 with several members of the RanGTPase-mediated nuclear transport pathway. Pulldown 140 
assays of GST-bound RanBP6 with nuclear and cytoplasmic fractions of HEK-293T cells 141 
showed that RanBP6 bound Ran only in the nuclear fraction where Ran is predominantly GTP-142 
bound. We also observed an interaction between RanBP6 and RCC1, a guanine nucleotide 143 
exchange factor that mediates the conversion of RanGDP to RanGTP in the nucleus (Fig. 1e).  144 
 145 
To gain a broader view of proteins that interacted with RanBP6, we affinity-purified RanBP6 146 
from A431 cells expressing a Dox inducible RanBP6-V5 construct and performed LC-MS/MS 147 
analysis of four independent experiments. We observed interactions of RanBP6 with 232 148 
proteins, including EGFR (Supplementary Data 3). This list of proteins was highly enriched for 149 
gene ontology pathways related to protein targeting to membranes (Supplementary Data 4). A 150 
considerable subset of proteins which associated with EGFR in our prior analysis of the EGFR 151 
interactome (84/431) also associated with RanBP6 (Fig. 1f)(Supplementary Data 5). 152 
Interestingly, this list of proteins did not include any of the canonical EGFR pathway members, 153 
but did include Nuclear pore complex protein Nup93 and multiple components of the SEC61 154 
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protein complex (Sec61α1, Signal sequence receptor subunit α and δ) which facilitates 155 
movement of EGFR between the cytoplasm and the endoplasmic reticulum in the process of 156 
routing the receptor toward the nucleus 13–15. Using GST-RanBP6 fusion protein as bait, we 157 
confirmed in whole cell lysates the interaction between RanBP6 and nuclear pore complex 93 158 
(Nup93), importin subunit α-1 (importin α1), importin subunit β-1 (importin β1), and the GTPase 159 
activating protein RanGAP1, a GTPase activating protein which hydrolyzes RanGTP into 160 
RanGDP in the cytoplasm (Fig. 1g). Taken together, our experiments identify RanBP6 as EGFR-161 
interacting protein and member of the Ran-GTPase nuclear transport pathway. 162 
 163 
RanBP6 represses EGFR transcription and EGFR signal output 164 
Several proteins that bind EGFR, such as CBL family members or ERBB receptor feedback 165 
inhibitor 1, play critical roles in EGFR regulation 4–6. To determine whether RanBP6 might play 166 
a role in regulating EGFR levels or function, we generated HEK-293T sublines expressing two 167 
different Dox-inducible RanBP6-short hairpin RNAs (shRNAs). RanBP6 knockdown with either 168 
hairpin increased EGFR protein levels (Fig. 2a).  169 
 170 
We next evaluated the effects of RanBP6 on EGFR mRNA levels. Dox-induced knockdown of 171 
RanBP6 raised EGFR mRNA levels, typically about 2-fold (Fig. 2b). Complete RanBP6 172 
depletion using the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 173 
system resulted in a more pronounced elevation of EGFR mRNA and protein levels (Fig. 2c). 174 
RanBP6 knockdown also increased the expression of a luciferase reporter cloned downstream of 175 
the EGFR promoter sequence, but had no effect on a control β-actin luciferase reporter (Fig. 2d), 176 
suggesting that RanBP6 regulates EGFR RNA levels through effects on EGFR promoter activity.  177 
 178 
Lastly, we examined whether the increase in EGFR levels associated with RanBP6 depletion 179 
resulted in increased EGFR pathway output. This was indeed the case, as demonstrated by 180 
increased phosphorylation of EGFR, the adapter protein Gab1, and downstream EGFR pathway 181 
members ERK1/2, Akt, and S6 kinase following EGF induction (Fig. 2e). Of note, the rate of 182 
EGF-induced EGFR protein degradation was comparable in the absence and presence of 183 
doxycycline, further supporting the conclusion that increased EGFR protein levels in RanBP6 184 
knock down cells were not the result of impaired EGFR protein degradation.  185 
 186 
RanBP6 promotes nuclear translocation of STAT3 187 
Members of the β-importin-like protein superfamily transport a variety of cargoes, including 188 
transcription factors. We hypothesized that RanBP6 might facilitate the nuclear transport of a 189 
transcription factor that regulates EGFR promoter activity. We therefore examined the 190 
subcellular localization of several transcription factors. We included the transcription factor 191 
STAT3 in our analysis because it associated with EGFR in our mass spectrometric analysis 192 
(Supplementary Data 1), had previously been shown to associate with EGFR 16–18, and has been 193 
proposed to enter the nucleus through an importin-mediated transport mechanism 19. RanBP6 194 
knockout cells showed decreased nuclear and increased cytoplasmic STAT3 levels (Fig. 3a). In 195 
contrast, we observed no changes in the subcellular localization of several other cancer-related 196 
proteins, including the transcription factors p53 and c-Jun, Retinoblastoma-associated protein 197 
(RB), p27Kip1, Forkhead box protein O3 (FOXO3), and Survivin (Fig. 3a and Supplementary Fig. 198 
3). We also examined the effects of RanBP6 on nuclear translocation of STAT3 by 199 
immunofluorescence. RanBP6 knockdown impaired interleukin 6-induced nuclear translocation 200 
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of STAT3, similar to the ATP-competitive Janus Kinases (JAK) inhibitor ruxolitinib (Fig. 201 
3b)(Supplementary Fig. 4).  202 
 203 
We next examined the effect of RanBP6 on STAT3-regulated gene expression. We observed 204 
reduced expression of an engineered STAT3-reporter gene following RanBP6 knockdown (Fig. 205 
3c). To evaluate the effects of RanBP6 on the expression of endogenous STAT3 target genes, we 206 
used Affymetrix gene expression arrays and single-sample gene set enrichment analysis 207 
(ssGSEA). Gene sets that have been reported to be activated by STAT3 (MsigDB, 208 
http://www.broadinstitute.org/gsea/msigdb/) showed lower enrichment scores in RanBP6 209 
knockdown cells whereas gene sets that are negatively regulated by STAT3 (Dauer-STAT3-210 
targets-DN) showed higher enrichment scores in RanBP6 knockdown cells (Fig. 3d). We 211 
confirmed these results by quantitative PCR for several of the genes that have been reported to 212 
be activated (PTGS2, MAFF and EFNB2) or repressed (IFIT1 and CPS1) by STAT3. These 213 
genes showed similar changes in expression following RanBP6 and STAT3 knockdown, 214 
respectively (Fig. 3e).  215 
  216 
RanBP6 represses EGFR transcription through STAT3 217 
Given our findings that RanBP6 regulates nuclear translocation of STAT3 and STAT3-218 
dependent transcription, we wondered whether RanBP6 might mediate transcriptional repression 219 
of EGFR through STAT3. We first examined the effect of STAT3 knockdown on EGFR mRNA 220 
levels using a doxycyline-inducible shRNA construct and observed increased EGFR mRNA and 221 
protein levels following STAT3 knockdown (Fig. 4a). We next examined whether EGFR might 222 
be a direct target of transcriptional repression by STAT3. Using the Jaspar transcription profile 223 
database (http://jaspar.genereg.net)20, we identified multiple putative STAT3 binding sites in a 224 
1.5 kb region upstream to the transcription starting site (TSS) of the EGFR gene (Supplementary 225 
Table 1).  We selected two regions, a proximal and a distal (EGFR_1, -1340:-1111; EGFR_2, -226 
223:-117), for further analysis. By performing an anti-STAT3 ChIP assay, we found that STAT3 227 
protein is recruited to these two specific regions and that the binding is lost upon RanBP6 228 
silencing (Fig. 4b). Similar binding was observed for PTGS2, a known STAT3 target gene, but 229 
not for the negative control HPRT.  230 
 231 
Since RanBP6 associated with both STAT3 and phosphorylated STAT3 (tyrosine 705)(Fig. 4c), 232 
we explored whether transcriptional repression of EGFR might be mediated by activated STAT3. 233 
Expression of a STAT3 mutant with constitutive nuclear localization (STAT3C) was sufficient to 234 
lower EGFR mRNA levels (Fig. 4d) whereas inhibition of STAT3 phosphorylation with the JAK 235 
kinase inhibitor ruxolitinib raised EGFR levels (Fig. 4e). Of note, RanBP6 silencing lost its 236 
ability to raise EGFR levels in the setting of sustained (12 hours) pharmacological p-STAT3 237 
blockade by ruxolitinib (Fig. 4f, compare EGFR ratios lane 6:lane 5 versus lane 2:lane 1) 238 
suggesting that RanBP6 represses EGFR transcription through activated STAT3.  239 
 240 
We also explored a potential contribution of exportin-1 (XPO1/CRM1) in this process because 241 
XPO1 associated with RanBP6 and EGFR in our mass spectrometric analyses (Supplementary 242 
Data 5) and CRM1 inhibition had been reported to reduce STAT3 levels in a breast cancer cell 243 
line 21. However, we observed no effects of CRM1 inhibition on RanBP6 or the levels of STAT3 244 
and acetylated STAT3 (Supplementary Fig. 5). 245 
 246 
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EGFR regulation by RanBP6 is disrupted in PTEN-deficient cells 247 
In our initial characterization of the interaction between EGFR and RanBP6 in A431 cells, we 248 
noted that EGF-stimulation (5 min, 100ng/mL) reduced the interaction between RanBP6 and 249 
EGFR (Fig. 5a). This suggested that RanBP6 might be part on an auto-regulatory mechanism 250 
where suppression of EGFR transcription by RanBP6 is temporarily inactivated following EGFR 251 
activation, perhaps to allow restoration of EGFR protein levels following ligand-induced 252 
receptor degradation. Similar to our observation in A431 cells, EGF reduced the association 253 
between RanBP6 and EGFR in HEK-293T cells. The effect of EGF on the RanBP6-EGFR 254 
association could be rescued by pretreatment of cells with the AKT kinase inhibitor MK-2206 255 
(Fig. 5b).  256 
 257 
We next examined the effect of the phosphatase and tensin homologue (PTEN), a negative 258 
regulator of the PI3K signaling pathway, on the interaction between EGFR and RanBP6. GST-259 
tagged RanBP6 associated with endogeneous EGFR in lysates from mouse embryonic fibroblasts 260 
(MEFs) but not PTEN knockout MEFs (Fig. 5c). Loss of PTEN not only impaired the interaction 261 
between EGFR and RanBP6, but also abrogated the effects of RanBP6 knockdown on EGFR 262 
mRNA levels (Fig. 5d), demonstrating that both RanBP6 functions are PTEN-dependent.  263 
 264 
Since PTEN is commonly silenced in cancer 22, we wondered whether PTEN status might affect 265 
the relationship between EGFR and RanBP6 RNA levels in human cancer cell lines. We 266 
examined this question across a panel of 877 genetically annotated human cancer cell lines 267 
included in the publically available Cancer Cell Line Encyclopedia (CCLE) 23. Consistent with 268 
our findings in isogenic models, we observed an inverse relationship between RanBP6 and 269 
EGFR mRNA levels (Fig. 5e, left panel). When cell lines where stratified by PTEN status, the 270 
inverse correlation between RanBP6 and EGFR mRNA levels was only present in cancer cell 271 
lines without PTEN alteration (Pearson product-moment correlation r = −0.22, p value = 2e−09) 272 
but not in cell lines with PTEN alteration (Pearson product-moment correlation r = −0.066, p 273 
value = 0.43)(Fig. 5e, right panels)(Supplementary Data 6). Taken together, our findings suggest 274 
that EGFR regulation by RanBP6 is disrupted in the setting of acute (e.g., EGF stimulation) or 275 
sustained (e.g., PTEN loss) PI3K pathway activation. Our observation that RanBP6 functions are 276 
dependent of the activation state of the PI3K pathway is reminiscent of the observation that PI3K 277 
pathway activity regulates the function of RanBP3 24. Unlike RanBP3, however, RanBP6 does 278 
not appear to be the recipient of an AKT-regulated phosphorylation signal since EGFR from 279 
lysates of PTEN-deficient cells also failed to bind bacterially purified GST-RanBP6 fusion 280 
protein which is not amenable to posttranslational modification.   281 
 282 
RanBP6 shows tumor suppressor-like activity in glioblastoma 283 
Aberrant activation of EGFR in human cancer typically occurs through alterations in the EGFR 284 
gene, but can also be the result of defects in physiologic EGFR feedback regulation 25. We 285 
therefore examined whether RanBP6 exhibits tumor suppressor-like activity. We examined this 286 
question in experimental models of glioblastoma (GBM) because we had observed in several 287 
GBMs focal deletions of the RANBP6 gene locus on chromosome arm 9p (9p24.1). These 288 
deletions occurred independently of deletions in CDKN2A (Fig. 6a), suggesting that they 289 
represented two independent events with selective pressure for the loss of each gene 290 
independently. Overall, approximately 40% of GBMs in the TCGA datasets showed loss of at 291 
least one RANBP6 allele. Copy loss at the RANBP6 gene locus was most common in the 292 
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“classical” GBM subgroup (Supplementary Fig. 6), which has been linked to deregulated EGFR 293 
activation  26. Copy loss at the RANBP6 gene locus was correlated with reduced RANBP6 294 
mRNA levels (Fig. 6b)(Supplementary Data 7). RANBP6 was lower in tumor tissue compared to 295 
non-tumoral brain tissue (Supplementary Fig. 7).  296 
 297 
We next examined the relationship between RanBP6 and EGFR expression in GBM. In human 298 
GBM tumor sections, we observed an inverse correlation between RanBP6 and EGFR protein 299 
levels (Supplementary Fig. 8) and RanBP6 knockdown upregulated EGFR expression in the 300 
human GBM cell line LN18 (Supplementary Fig. 9), consistent with earlier results in HEK-293T 301 
cells and MEFs.  302 
 303 
Western blotting of five patient-derived GBM tumor spheres showed markedly decreased 304 
RanBP6 protein levels in one of the five tumor sphere lines (TS516 cells) (Fig. 6c). We stably 305 
transduced TS516 cells with a Dox-inducible RanBP6-V5 construct and observed a reduction in 306 
soft agar colony formation and reduced EGFR protein levels upon Dox treatment (Fig. 6d-e). 307 
Induction of RanBP6-V5 also reduced tumor growth and EGFR expression in subcutaneous 308 
TS516 xenografts (Fig. 6f).  RanBP6 reconstitution similarly reduced soft agar growth in 309 
RanBP6-low SF268 GBM cells (Supplementary Fig. 10).  310 
 311 
Lastly, we examined the effect of RanBP6 silencing on in vivo glioma growth using the RCAS-312 
tva mouse glioma model. The RCAS-tva system utilizes an avian leukosis virus based vectors 313 
(RCAS) to mediate gene transfer into cells specifically expressing the tv-a receptor 27. We 314 
injected newborn N-tva mice, that express the Tv-a under the control of the Nestin promoter, a 315 
well-known marker of neural stem and progenitor cells, with cells producing the RCAS 316 
retroviruses carrying the platelet-derived growth factor-B (PDGFB) in combination with either a 317 
mouse RanBP6 shRNA or an shRNA for Luciferase as control. RanBP6 knockdown decreased 318 
survival, with mice injected with the RanBP6 shRNA living an average of 189 days (n = 10) and 319 
control mice living 275.5 days (n = 14)(p = 0.047, log rank test)(Fig. 6g) and promoted the 320 
development of higher grade gliomas (Fig. 6h and Supplementary Fig. 11). Cells derived from 321 
RanBP6 knockdown tumors showed increased EGFR mRNA levels (Fig. 6i).  322 
 323 
DISCUSSION 324 
 325 
Our study introduces RanBP6, a protein with currently unknown functions, as member of the 326 
importin β superfamily and EGFR regulator. EGFR continuously cycles between the plasma 327 
membrane and the endosomal compartment. Activation of EGFR is followed by a series of 328 
molecular events that contain EGFR signal strength and duration. In parallel, EGFR signaling is 329 
reinforced through the induction of autocrine ligands which are unable to induce EGFR 330 
downregulation and through an increase in EGFR mRNA levels 28–30. These positive feedback 331 
mechanisms aim to restore EGFR levels, work on the same timescale as negative feedback 332 
mechanisms, and protect the robustness of ligand-induced mitogenic stimulation 31. Our results 333 
suggest that RanBP6 contributes to cellular EGFR homeostasis by constitutively repressing 334 
EGFR transcription and being “switched off” in the setting of increased cellular EGFR demand, 335 
such as ligand-induced EGFR degradation (Fig. 7).  336 
 337 
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EGFR has been reported to localize to the nucleus (for review see 32,33) through a process that 338 
involves trafficking of EGFR from the plasma membrane to the endoplasmic reticulum (ER), 339 
binding to the Sec61 translocon, retro-translocation from the ER to the cytoplasm, and 340 
association with Importin β 13. Once in the nucleus, EGFR has been shown to act as a 341 
transcriptional co-activator for several genes 34,35. Our data is consistent with previous findings 342 
that EGFR may serve as a scaffold to shuttle a fraction of STAT3 molecules toward the nucleus 343 
16,36–38 and that STAT3 molecules enters the nucleus through an importin-mediated nuclear 344 
transport mechanism 19. Our observation that STAT3 is a direct transcriptional repressor of 345 
EGFR, which has not previously been reported, is consistent with the recent report of increased 346 
EGFR signaling following JAK-STAT inhibition 39 and may have implications for strategies to 347 
develop STAT3 inhibitors for cancer therapy. Further studies are needed to determine how 348 
RanBP6-facilitated nuclear transport of STAT3 affects the substantial repertoire of STAT3 349 
associated cellular functions and dissect transcriptional programs regulated by STAT3 and 350 
phosphorylated STAT3 40–42.  351 
 352 
EGFR is one of the first receptor tyrosine kinases linked to human cancer and represents an 353 
important drug target in oncology 43. Aberrant activation of EGFR and other ErbB receptor 354 
family members in cancer is primarily attributed to increased gene copy numbers or gain-of-355 
function mutations in the genes encoding these receptors. However, unbalanced ErbB activation 356 
in cancer can also result from defects in EGFR feedback regulation 25. ERBB receptor feedback 357 
inhibitor 1 (ERRFI; also known as Mitogen-inducible gene 6 protein), for example, which 358 
encodes a cytosolic protein that directly binds and inhibits ErbB-family receptors, is deleted in 359 
cancer and has shown tumor suppressor activity in experimental cancer models 44,45. Our data 360 
suggests that RanBP6 possesses similar tumor suppressor-like activity, at least in glioblastoma. 361 
While RanBP6 did not affect a variety of cancer-associated signaling molecules, including other 362 
receptor tyrosine kinases (e.g. PDGFRA, PDGFRB, ERBB2 and ERBB3)(Supplementary Fig. 363 
12), we cannot exclude the possibility that the tumor suppressor activity of RanBP6 is mediated 364 
by effects that go beyond its effects on EGFR. The nuclear transport machinery is tightly 365 
regulated and can be disrupted in cancer through mutations or altered expression of nuclear 366 
transport components or disruption of the RanGTP/GDP gradient 46,47. Taken together, our data 367 
identifies a link between the Ran-GTPase nuclear transport pathway and key cancer signaling 368 
pathways which warrant further study as inhibitors targeting nuclear transporters enter clinical 369 
evaluation as cancer therapeutics 41. 370 
  371 
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METHODS 372 
 373 
Cell Lines and Reagents 374 
Epidermoid carcinoma cell line A431, Human Embrionic Kidney HEK-293T, DF1, Human 375 
Glioma cell lines LN18, T98G, A172 were purchased from ATCC. SF268 and SF295 were 376 
obtained from NCI. SKMG-3 cells were a gift of Hans Skovgaard (Rigshospitalet, Oslo). HEK-377 
293T and LN18 were authenticated by SNPs analysis. GBM tumor spheres were derived at the 378 
MSKCC Brain Tumor Center according to MSKCC IRB guidelines. MEF PTEN lox/lox were 379 
kindly provided by Hong Wu (UCLA). All the cell lines were routinely checked for Mycoplasma 380 
contamination by PCR analysis. DNA fingerprinting was previously performed for 381 
authentication of all glioma cell lines 48. Antibodies to RanBP6 (ab74448; 1:1000), EGFR 382 
(ab52894; 1:960 for immunofluorescence staining), RanGAP1 (ab92360; 1:200) and CRM1 383 
(ab24189, 1:1000) were purchased from Abcam. Antibodies to EGFR (#2085; 1:500 for GST-384 
RanBP6 pulldown and 1:1000-5000 for immunoblot), pEGFR Tyr1068 (#3777; 1:1000), Gab1 385 
(#3232; 1:1000), pGab1 Tyr627 (#3231; 1:1000), pErk1/2 Thr202/Tyr204 (#9101; 1:1000), Akt 386 
(#9272S; 1:1000), pAkt Ser473 (#4051; 1:1000), S6 (#2317S; 1:1000), pS6 Ser240/244 (#5364; 387 
1:1000), PTEN (#9556; 1:1000), STAT3 (# 12640S; 1:1000), pSTAT3 Tyr705 (#9145S; 388 
1:1000), Ac-STAT3 Lys685 (#2523S; 1:250), H3 (#4499S; 1:5000), p27Kip1 (#2552, 1:500), 389 
RB (#9309, 1:1000), and Foxo3a (#2497, 1:1000) were purchased from Cell Signaling. 390 
Antibodies to GST (G7781; 1:50000), V5 agarose affinity gel (A7345; 6μl antibody/1mg lysate), 391 
Importin α (I1784; 1:1000), Importin β (I2534; 1:500), Ran (R4777; 1:1000), Vinculin (V9131; 392 
1:10000), and β-Actin (A2228; 1:50000) were purchased from Sigma. Antibody to V5 (P/N 46-393 
1157; 1:5000) is from Invitrogen. Antibodies against Nup93 (SC-374399; 1:500), RCC1 (SC-394 
55559; 1:1000), STAT3 (SC-482; 1:100 for immunofluorescence staining), Tubulin (SC-23948; 395 
1:10000) and Survivin (SC-17779; 1:200) were purchased from Santa Cruz. The AKT inhibitor 396 
MK2206, XPO1 inhibitor KPT330 (selinexor) and KPT185 were purchased from Selleckchem, 397 
and the JAK inhibitor Ruxolitinib (Novartis) was kindly provided by Ross Levine.  398 
 399 
RanBP6 expression vectors and knockdown reagents 400 
To generate the RANBP6 expressing lentiviral construct, RanBP6 was PCR amplified using 401 
pBluescriptR- human RanBP6 (Open Biosystems, clone ID 30347107) as template and the 402 
primers pLenti6.3-RanBP6-V5 Forward and Reverse listed in Supplementary Table 2. The 403 
amplified product was then transferred into a lentiviral expression plasmid (pLenti6.3/V5-DEST, 404 
Invitrogen) with the Gateway recombination technology using the pDONR221 vector as an 405 
intermediate vector. Construct was Sanger sequence verified. GST-RanBP6 was generated by 406 
sub-cloning the amplified PCR product of human RanBP6 to a digested GST vector (pGEX6.2, 407 
GE healthcare). TRIPZ RanBP6 inducible shRNAs from Open Biosystem (V3THS_374866 and 408 
V3THS_374867) were used to knockdown human RanBP6. Mouse specific RanBP6 hairpin was 409 
designed and cloned into the mir30 based retroviral MLP vector (kindly provided by Scott Lowe) 410 
and subsequently into the RCAS vector (Supplementary Table 3). RanBP6 cDNA that is resistant 411 
to the human hairpin V3THS_374867 was generated by PCR cloning of human RanBP6 cDNA 412 
to MSCV-MIGR1-GFP plasmid (Addgene #27490). Three codons inside the hairpin sequence 413 
were swapped to generate silence mutations by site-directed mutagenesis kit (Agilent 414 
Technologies, catalog #210519-5). TRIPZ STAT3 inducible shRNAs is from Open Biosystem 415 
(V3THS_376017).  416 
 417 
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Cell line Transfections and Infections 418 
Adherent lines were grown in DMEM 10% FBS (Omega scientific, FB-11). Neurospheres were 419 
grown in NeuroCult NS-A Proliferation Kit (Stem Cell Technology) supplemented with Heparin 420 
(2mg/ml), human EGF and bFGF (20ng/ml each). Lentivirus and retrovirus were generated by 421 
co-transfection of retro or lentiviral plasmids and the packaging VSVg for retrovirus and 422 
pMD2G and psPAX2 for lentivirus in Gp2-293 using Calcium Phosphate. High titer virus was 423 
collected at 36 and 60 hours following transfection and used to infect cells for 12 hours. TS516 424 
was spin-infected for 2 hours at 1000rpm. Transduced cells were selected after 48 hours from the 425 
last infection with blastidicin (2-5μg/ml), G418 (500-800μg/ml) and puromycin (3μg/ml) 426 
according to the plasmid antibiotic resistance. DF1 cells were grown at 39°C in DMEM (ATCC) 427 
containing 10% FBS (SIGMA, F7524). DF1 cells were transfected with the RCAS viral 428 
plasmids, using Fugene 6 Transfection reagent (Roche), accordingly to manufacturer's protocol. 429 
EGF time course experiments were carried out in cells serum starved for 16 hours and then 430 
stimulated with 100ng/ml EGF for the indicated time. EGF and Doxycycline were from SIGMA.  431 
 432 
Immunoprecipitation and Immunoblotting  433 
A431 PTEN isogenic-Dox-inducible RanBP6 V5 cells were induced or not with 1μg/ml Dox and 434 
were lysed 36 hours later in JS lysis buffer (50mM HPES, 150mM NaCl, 1% Glycerol, 1% 435 
Triton X-100, 1.5mM MgCl2, 5mM EGTA). Lysates were precleared by incubation for 1 hour at 436 
4°C with Protein G/A (Calbiochem) blocked in 5% BSA and then incubated with the V5 437 
antibody (Invitrogen) for 2 hours followed by 1 hour incubation with Protein G/A. The 438 
immunoprecipitates were washed 4 times with JS lysis buffer and bound proteins were eluted in 439 
Laemmli Buffer. Proteins for immunoblot analysis were run either on 4-12% Bis-Tris SDS-440 
PAGE gels (Invitrogen) or on house-made SDS-PAGE gels and transferred to nitrocellulose 441 
membrane (Amersham). Membranes were incubated in blocking buffer (5% milk 0.1% Tween, 442 
10 mM Tris at pH 7.6, 100 mM NaCl) and then with primary antibody either 1 hour at room 443 
temperature or overnight at 4°C according to the antibody. Anti-mouse or rabbit-HRP conjugated 444 
antibodies (Jackson Immunoresearch) were used to detect protein by chemiluminescence with 445 
ECL (Amersham). Uncropped scan of the main Western blots are reported in supplementary 446 
figures 14-16. 447 
GST fusion protein purification and pull down assay 448 
BL21 cells transformed with pGEX6p2-RanBP6 were grown in 200 ml of LB medium at 37°C to 449 
an A600 of 0.4-0.7. Protein was induced by culturing in the presence of 1mM of isopropyl-thio-D-450 
galactopyranoside (IPTG) at 20°C for 16 hours. Bacterial pellets were collected by centrifugation 451 
at 7700xg for 10 minutes at 4°C. Pellets were resuspended in 10 ml of cold lysis buffer (1% 452 
Triton X-100, 1mM of dithiothritol, 1X protease inhibitor cocktail I and 1X phosphatase 453 
inhibitor cocktail in 1X PBS). Resuspended bacterial lysates were sonicated (41% amplitude, 4 454 
pulses of 10 seconds/cycle) and centrifuged at 12,000 rpm for 15 minutes at 4°C. The 455 
supernatants were transferred to 15 ml falcon tube and incubated with 50% GST beads slurry at 456 
4°C for 2-4 hours. Supernatants with beads were then sedimented at 500 xg at 4°C for 5 minutes, 457 
and washed twice with ice-cold wash buffer, and washed again with 1X PBS without detergent. 458 
Beads were finally resuspended in 1-2 bed volumes of GST maintenance buffer (50mM Tris, 459 
100mM NaCl 1mM EDTA, 10% glycerol, 1mM dithiothritol, and 1X protease and phosphatase 460 
inhibitors). The proteins were aliquoted, snap frozen with liquid nitrogen, and stored at -80°C. 25 461 
μg of GST empty vector and pGEX-RanBP6 beads were incubated with 500 μg of cell lysates on 462 
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a rotator in the cold room for 2-4 hours. Lysates from HEK-293T were from cells either serum 463 
starved for 12 hours and stimulated with EGF (100ng/ml) or grown in full media. The beads 464 
were sedimented, washed three times with cold lysis buffer (Cell signaling, catalog #9803S) with 465 
5 minutes incubation at 4°C in between washes, and then lysed with 2X SDS sample buffer (Bio-466 
rad, #161-0737). 467 
 468 
Mass Spectrometry 469 
Lysates from A431 cells serum starved for 24 hours and stimulated with EGF (100ng/ml) for 5 470 
minutes and from A431-Dox-inducible-RanBP6-V5 cell serum starved for 24 hours were 471 
precleared by ultracentrifugation at 45000rpm for 45 minutes. For the immunopurification of 472 
EGFR interactors, 4mg of lysate were incubated for 2 hours and 30 minutes at 4°C with 100ul 473 
(slurry 50%) of Cetuximab antibody conjugated to magnetic Dynabeads protein G (Life 474 
Technologies).  For the immunopurification of the RanBP6 interactors, 2 mg of lysates were 475 
incubated overnight with 12μl anti-V5 agarose affinity gel (Sigma). Supernatants were then 476 
removed and beads were washed 6 times with lysis buffer. The EGFR complexes were eluted in 477 
two rounds using 500mM NH4OH and 1mM EDTA in two rounds of 10 minutes. The RanBP6-478 
V5 complexes were instead obtained by V5 peptide (Sigma) elution competition in two rounds of 479 
20 minutes.  Negative controls were carried along by precipitating proteins with mouse IgG 480 
instead of Cetuximab and with V5 agarose affinity gel in A431 parental cells. Three and four 481 
replicates for EGFR and V5 immunoaffinity respectively were performed. Elutions were 482 
resolved using SDS-polyacrylamide gel electrophoresis, followed by staining with Coomassie 483 
Blue and excision of the separated protein bands; in all experiments, prominently stained EGFR 484 
band (Mr~ 170 kDa) and RanBP6-V5 band (Mr~ 125 kDa) were always excised as an individual 485 
protein band for analysis.  This was done to enhance the dynamic range encountered during 486 
analysis of complex protein mixtures and detection of peptides arising from proteins found in 487 
less abundant amounts compared to EGFR and RanBP6-V5. In situ trypsin digestion of 488 
polypeptides in each gel slice was performed as described 49. The tryptic peptides were purified 489 
using a 2-µl bed volume of Poros 50 R2 (Applied Biosystems, CA) reversed-phase beads packed 490 
in Eppendorf gel-loading tips 50. The purified peptides were diluted to 0.1% formic acid and then 491 
subjected to nano-liquid chromatography coupled to tandem mass spectrometry (nanoLC-492 
MS/MS) analysis as follows. Peptide mixtures (in 20 µl) were loaded onto a trapping guard 493 
column (0.3 x 5mm Acclaim PepMap 100 C18 cartridge from LC Packings, Sunnyvale, CA) 494 
using an Eksigent nano MDLC system (Eksigent Technologies, Inc. Dublin, CA) at a flow rate 495 
of 20 µl/min.  After washing, the flow was reversed through the guard column and the peptides 496 
eluted with a 5-45% acetonitrile gradient over 85 min at a flow rate of 200 nl/min, onto and over 497 
a 75-micron x 15-cm fused silica capillary PepMap 100 C18 column (LC Packings, Sunnyvale, 498 
CA). The eluent was directed to a 75-micron (with 10-micron orifice) fused silica nano-499 
electrospray needle (New Objective, Woburn, MA).  The electrospray ionization needle was set 500 
at 1800 V. A linear ion quadrupole trap-Orbitrap hybrid analyzer (LTQ-Orbitrap, ThermoFisher, 501 
San Jose, CA) was operated in automatic, data-dependent MS/MS acquisition mode with one MS 502 
full scan (450-2000 m/z) in the Orbitrap analyzer at 60,000 mass resolution and up to ten 503 
concurrent MS/MS scans in the LTQ for the ten most intense peaks selected from each survey 504 
scan. Survey scans were acquired in profile mode and MS/MS scans were acquired in centroid 505 
mode. The collision energy was automatically adjusted in accordance with the experimental 506 
mass (m/z) value of the precursor ions selected for MS/MS. Minimum ion intensity of 2000 507 
counts was required to trigger an MS/MS spectrum; dynamic exclusion duration was set at 60 s. 508 
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Initial protein/peptide identifications from the LC-MS/MS data were performed using the Mascot 509 
search engine (Matrix Science, version 2.3.02; www.matrixscience.com) with the human 510 
segment of Uniprot protein database (20,273 sequences; European Bioinformatics Institute, 511 
Swiss Institute of Bioinformatics and Protein Information Resource). The search parameters 512 
were as follows: (i) two missed cleavage tryptic sites were allowed; (ii) precursor ion mass 513 
tolerance = 10 ppm; (iii) fragment ion mass tolerance = 0.8Da; and (iv) variable protein 514 
modifications were allowed for methionine oxidation, cysteine acrylamide derivatization and 515 
protein N-terminal acetylation. MudPit scoring was typically applied using significance 516 
threshold score p<0.01. Decoy database search was always activated and, in general, for merged 517 
LS-MS/MS analysis of a gel lane with p<0.01, false discovery rate averaged around 1%. 518 
Scaffold (Proteome Software Inc., Portland, OR), version 4_4_4 was used to further validate and 519 
cross-tabulate the tandem mass spectrometry (MS/MS) based peptide and protein identifications. 520 
Protein and peptide probability was set at 95% with a minimum peptide requirement of 1.  521 
 522 
Gene ontology analysis 523 
The gene ontology enrichment was performed using the Gene Ontology Consotrium website 524 
(www.geneontology.org), through the analysis tools from the PANTHER Classification System, 525 
by uploading the list of the Uniprot_IDs of the proteins identified in the mass spectrometry 526 
experiments. The enrichment results were filtered to reduce the number of redundant GO classes, 527 
by using the “Clusterprofiler” and “GOSemSim” packages in R (Yu et al., 2010; Yu et al., 2012). 528 
All code used to analyze the data and generate the plots is available at: 529 
https://github.com/squatrim/oldrini2017. 530 
 531 
CRISPR/Cas9-mediated knockout of RanBP6 532 
RanBP6 CRISPR constructs were generated with guided RNAs that target human RanBP6 533 
sequence (Supplementary Table 3) and pX330 CRISPR/Cas9 vector (Addgene #42230) 51. 534 
pX330 vector was digested with BbsI and ligated with annealed oligonucleotides. HEK-293T 535 
cells were transfected with three different sgRanBP6 constructs. Clonal isolations were 536 
performed by serial dilutions (0.5 cells/well). Genomic DNA extractions were performed with 537 
the cell lines that are recovered from single cells. Each of the clones was examined by 538 
SURVEYOR nuclease assays. The PCR products that were amplified from SURVEYOR primers 539 
(Supplementary Table 3) were further validated by Sanger sequence to confirm the indels. Out of 540 
all the clones that were generated by three independent sgRNAs, we selected the one that has the 541 
best knockout efficiency for further experiments. 542 
 543 
Subcellular fractionation assay 544 
Cytoplasmic and nuclear fractions of HEK-293T cells serum starved for 12 hours and treated 545 
either with EGF (100ng/ml) for 15 minutes or IL6 (10ng/ml) for 30 minutes were prepared with 546 
nuclear extract kit (Active Motif, #40010.) The cytoplasmic fractions were extracted with 547 
hypotonic buffer. The nuclear pellets were stringently washed 4 times before addition of nuclear 548 
lysis buffer, vortexed, and briefly sonicated (10% amplitude for 5 seconds) before 30 minutes’ 549 
incubation on a rotator at 4°C. For subcellular analysis of STAT3, the lysates were normalized to 550 
protein concentration. For GST-RanBP6 pulldown with Ran and RCC1, the fractionated lysates 551 
were normalized to the cell number (cytoplasm:nuclear = 50:1).       552 
 553 
Reverse Transcription Quantitative PCR 554 
 14 
 
RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. 555 
For reverse transcription PCR (RT-PCR), 500ng of total RNA was reverse transcribed using the 556 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA was used for 557 
quantitative PCR using SYBR® Green ERTM kit (Invitrogen) according to the manufacturer’s 558 
instructions. Quantitative PCRs were run and the melting curves of the amplified products were 559 
used to determine the specificity of the amplification. The threshold cycle number for the genes 560 
analyzed was normalized to GAPDH and HPRT. Sequences of the primers used are listed in 561 
Supplementary Table 4 and primers for human RANBP6 (PPH13358B), ERBB2 (#PPH00209B-562 
200) and ERBB3 (#PPH00463B-200) are from Qiagen. 563 
  564 
Luciferase assay 565 
The promoter constructs of EGFR and Actin (ACTB) were purchased from SwitchGear 566 
Genomics (Product ID: #S714178 and #S717678). For measuring EGFR promoter activity, 567 
HEK-293T cells expressing Doxycycline inducible shRanBP6 were either treated with or 568 
without Doxycycline for 72 hours, and were further serum starved for 16 hours. 50 ng of Actin 569 
or EGFR promoter construct and 10 ng of cypridina control were co-transfected to the cells with 570 
Fugene. The luciferase activities of renilla and cypridina were measured 48 hours after 571 
transfection by following the manufacturer’s protocol (LightSwitch Dual Assay System, 572 
SwitchGear Genomics #DA010). STAT3 reporter for measuring the transcriptional activity of 573 
STAT3 was purchased from Qiagen (#CCS-9028L). For STAT3 reporter assay, both HEK293T 574 
and HEK293T-RanBP6 cell lines were treated with or without Doxycycline for 72 hours. Both of 575 
the cell lines were transfected with 100 ng of STAT3 reporter construct. The luciferase assay was 576 
developed by using Dual-Glo Luciferase Assay System from Promega (Catalog #E2920). The 577 
cells were seeded at a concentration of 15,000 cells/well in the 96-well plate, and were 578 
transfected at 60-80% confluence. Each measurement was done in biological triplicates with 579 
SpectraMax M5 multi-mode microplate readers (Molecular Devices). 580 
 581 
Gene expression array and ssGSEA  582 
HEK-293T cells expressing Doxycycline inducible RanBP6 hairpins were either treated with or 583 
without Doxycycline for 72 hours, and further serum starved for 16 hours. Total RNA was 584 
extracted with Qiagen RNeasy Mini Kit. The quality of the RNA was evaluated using Agilent 585 
BioAnalyzer RNA nano assay, and the high-quality RNA samples were processed for microarray 586 
at the Integrated Genomics Operation (IGO) at MSKCC. In summary, 500 ng of the RNA was 587 
reverse transcribed to double-stranded cDNA. The cDNA was used as a template for in vitro 588 
transcription with biotin-labelled uridine triphosphate at 37°C for 16 hours. The biotin-labelled 589 
cDNA was fragmented, and processed to hybridization cocktail to be hybridized to the GeneChip 590 
Human Genome U133 Plus 2.0 arrays (Affymetrix) according to the Affymetrix GeneChip 591 
protocol. Each sample was done in biological triplicates. Expression array analysis was 592 
completed in R (version 3.2.2) using the Bioconductor suite. The ‘affy’ package was used for 593 
robust multi-array average normalization followed by quantile normalization. For genes with 594 
several probe sets, the median of all probes had been chosen. Data are available online at NCBI 595 
GEO, Accession Number GSE76943. Single-sample Gene Set Enrichment Analysis (ssGSEA) 596 
has been performed in R using the ‘gsva’ function of the ‘gsva’ package. STAT3-related gene 597 
lists were downloaded from the Molecular Signatures Database (MSigDB) at the Broad institute 598 
(http://software.broadinstitute.org/gsea/msigdb). All code used to analyze the data and generate 599 
the plots is available at: https://github.com/squatrim/oldrini2017. 600 
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 601 
Chromatin Immunoprecipitation 602 
ChIP was performed as described in Frank et al. 52.  LN18 cells were treated with or without 603 
doxycycline and starved overnight with DMEM without serum. Cells were fixed with 1% 604 
formaldehyde for 15 min, stopped with 0.125 M glycine for 5 min, and washed twice with PBS. 605 
Cell pellets were sonicated for 6 min at 20% amplification (15 sec on followed by 60 sec off) 606 
followed by 2 min sonication at 40% (15 sec on followed by 60 sec off) with a Branson 450 607 
Sonifier. Lysates were precleared with Protein A/G beads (Santa Cruz) and incubated at 4°C 608 
overnight with 5 μg of polyclonal antibody specific for STAT3 (sc-482, Santa Cruz), or normal 609 
rabbit immunoglobulins (Santa Cruz). DNA was eluted in 100 μl of water and 5 μl were analyzed 610 
by qRT-PCR with SYBR Green (Applied Biosystems). The amplification product was expressed 611 
as a percentage of the input for each condition. The HPRT gene promoter was used as negative 612 
control 53. Primers used to amplify sequences surrounding predicted binding sites were designed 613 
using the Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) based on 614 
STAT3 binding site prediction using the Jaspar transcription profile database 615 
(http://jaspar.genereg.net)20 and the MatInspector software (http://www.genomatix.de). 616 
 617 
Immunofluorescence 618 
HEK-293T cells were seeded at 10,000 cells/well on 12mm poly-D-lysine and fibronectin coated 619 
rounded coverslip in 24-well plate and cultured in presence of 2 μg/ml of Doxycycline for 4 days 620 
with the last 16-18 hours in serum-starved condition. 1 μM of Ruxolitinib was applied to the 621 
culture for 4 hours and 10 ng/ml IL-6 for 30 min. Cells were fixed in 3.2% PFA in PBS for 20 622 
min, washed three times in PBS, incubated for 20 min in blocking solution (10% Donkey or Goat 623 
serum in 0.1% Triton-X PBS), incubated for 2 hours with 1:100 Rabbit anti-STAT3 (Santa Cruz, 624 
sc-842) in blocking solution, washed three times in PBS, incubated for 1 hour with 1:500 anti-625 
rabbit A488 (Invitrogen) in 0.1% Triton-X PBS, washed three times in PBS and mounted with 626 
Vectashield HM- DAPI (Vector Laboratories, H-1500). Cultures were imaged with Leica TCS 627 
SP5-II microscope and analyzed using a standardized Metamorph macro. STAT3 signal was first 628 
threshold to select the signal over the background, then the DAPI image was used to subdivide 629 
the threshold STAT3 signal into nuclear and cytoplasmic and ratio was calculated. For the 630 
staining of human GBM tissue sections, tumors were formalin-fixed, paraffin-embedded, cut into 631 
5 μm sections, and stained with DAPI (molecular probes, D3571), RanBP6 (polyclonal, 632 
ab74448, Abcam; 1:200) and EGFR (clone EP38Y, ab52894, Abcam; 1:960). Several fields of 633 
view were selected by a neuropathologist for further analysis. Specificity of RanBP6 staining and 634 
lack of cross-reactivity for RanBP5 was determined in normal tissue sections and HEK293 cells 635 
transfected with cDNA for RanBP6 or RanBP5.  Image acquisition, registration, segmentation, 636 
and quantification were performed using the method previously described 54. 637 
 638 
Soft agar assay 639 
TS516 cells were seeded in triplicates at 300,000 cells/well in Neurocult media containing 0.4% 640 
Noble agar (SIGMA A5431) and growth factor supplements (20ng/mL EGF, 10ng/mL bFGF) 641 
and SF268 at 50,000cells/well in DMEM 10% FBS. Cells were plated between two layers of 642 
Neurocult media and growth factors or DMEM and FBS containing 0.65% Nobel agar. Noble 643 
agar layers were containing Dox at 1.2μg/ml. Colonies were stained 3/4 weeks after plating with 644 
either crystal violet (0.005%) (SIGMA V5265) and quantified using imagine software (Oxford 645 
Optronix) and an image processing algorithm (Charm algorithm, Oxford Optronix). 646 
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 647 
Evaluation of glioma growth in-vivo 648 
For the TS516 xenograft model, 4-6 weeks old female SCID mice were injected subcutaneously 649 
with 106 glioma cells, which were suspended in 100μL of a 50:50 mixture of growth media and 650 
Matrigel (BD #356237). Mice were then randomly assigned to treatment groups (Dox or 651 
control). Ntv-a mice, and procedures for RCAS-mediated gliomagenesis have been described 652 
previously 55. Ntv-a pups were injected with a total of 200,000 DF1 cells transfected with various 653 
constructs: 100,000 RCAS-PDGFB plus 100,000 RCAS-shRanBP6 or RCAS-shLuc. After 654 
injection of the DF1 cells during the newborn period, mice were aged until they developed 655 
symptoms of disease (lethargy, poor grooming, weight loss, macrocephaly). Samples in panel 6h 656 
are derived from tumors generated in a Ntv-a; Ink4a/Arf null background. RCAS-shRanBP6 and 657 
RCAS-shLuc constructs express a EGFP reporter that allowed to isolate the tumor cells by 658 
FACS. For the derivation of primary cells for FACS analysis, tumors were digested to a single-659 
cell suspension by 10 min of incubation at 37 °C with 5 ml of papain digestion solution (0.94 mg 660 
ml−1 papain (Worthington), 0.48 mM EDTA, 0.18 mg ml−1 N-acetyl-L-cysteine (Sigma) and 0.06 661 
mg ml−1 DNase I (Sigma) diluted in Earl's Balanced Salt Solution (EBSS). After digestion, the 662 
enzyme was inactivated by the addition of 2 ml of 0.71 mg ml−1 ovomucoid (Worthington). The 663 
cell suspension was then passed through a 40-μm mesh filter to remove undigested tissue and   664 
centrifuged at a low speed (750 r.p.m.) to remove debris and obtain the cell pellet 55. Cells were 665 
then resuspended in 500μl of PBS to be sorted. All animal experiments were performed 666 
according to protocols approved by the by the Institutional Animal Care and Use Committee of 667 
Memorial Sloan-Kettering Cancer Center and CNIO-ISCIII Ethics Committee for Research and 668 
Animal Welfare (CEIyBA) and they were performed in accordance with the guidelines stated in 669 
the International Guiding Principles for Biomedical Research Involving Animals, developed by 670 
the Council for International Organizations of Medical Sciences (CIOMS). 671 
 672 
Statistical analysis 673 
Data are presented throughout as mean and SD, except otherwise indicated. Results were 674 
analyzed by unpaired two-tailed Student's t-tests unless otherwise noted and were considered 675 
statistically significant if P < 0.05. Kaplan–Meier survival curve was produced with GraphPad 676 
Prism; P value was generated using the Log-Rank statistic. 677 
 678 
Data availability 679 
The microarray data have been deposited in the NCBI GEO database under the accession code 680 
GSE76943. The proteomic data have been deposited in the UCSD MassIVE database 681 
(https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp) under MassIVE accession IDs  682 
MSV000081631 and MSV000081632. The CCLE data referenced during the study are available in a 683 
public repository from the cBio Portal 56 using the “cgdsr” package. The TCGA GBM and 684 
REMBRANDT data referenced during the study are available in a public repository from 685 
GlioVis data portal (http://gliovis.bioinfo.cnio.es) 57. All code used to analyse the data and 686 
generate the plots is available at: https://github.com/squatrim/oldrini2017. All the other data 687 
supporting the findings of this study are available within the article and its supplementary 688 
information files and from the corresponding authors upon reasonable request. 689 
  690 
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FIGURE LEGENDS 856 
 857 
Figure 1. Importin β-like protein RanBP6 interacts with EGFR  858 
(a) Left panel, schematic representation of EGFR immunoaffinity purification and LC-MS/MS 859 
analysis in A431. Right panel, plot showing the 5 top categories of the Gene Ontology 860 
enrichment analysis of the EGFR associated proteins. (b) List of the unique peptides for RanBP6 861 
identified in the MS analysis and the replicate in which the peptide was identified are indicated 862 
in the table. (c) Co-immunoprecipitation of EGFR and V5 epitope tagged RanBP6-V5 in A431 863 
cells. Top panel, IP using V5 antibody; bottom panel, immunoblot of whole cell lysates (WCL). 864 
(d) Conserved domains within the family of Importin β-related Proteins. RanBP6 includes an 865 
Importin β-like N-terminal domain (Imp. N-ter), seven HEAT repeats, and a putative Ran 866 
Binding Domain (RBD). The number to the right of each protein shows the total number of 867 
amino acids. (e) RanBP6 interacts with nuclear but not cytoplasmic Ran-GTPase. Subcellular 868 
fractionation of HEK-293T cells (right panel) shows that Ran is present in both nuclear and 869 
cytoplasmic compartments, but only interacts with RanBP6 in the nuclear fraction (left panel). 870 
(f) Venn diagram representing overlapping proteins between the RanBP6-V5 and the EGFR 871 
immunoaffinity purifications. See Supplementary Data 5.  (g) GST pull down assay confirms the 872 
interaction of RanBP6 with importin-α1, importin-β1, RanGAP1, and nuclear pore complex 93 873 
(NUP93) in HEK-293T whole cell lysates. 874 
 875 
Figure 2. RanBP6 regulates EGFR levels and EGFR signal output  876 
(a) RanBP6 knock-down (KD) raises EGFR protein levels in HEK-293T cells; Dox, 877 
doxycycline. (b) RanBP6 KD increases EGFR mRNA levels in HEK-293T cells. Shown are RT-878 
qPCR results. (c) CRISPR/Cas9-mediated knockout of RanBP6 increases EGFR mRNA (left 879 
panel) and EGFR protein (right panel) levels in HEK-293T cells. (d) RanBP6 KD increases 880 
transcription of a Luciferase reporter gene from EGFR promoter, but not from the β-actin 881 
(ACTB) promoter, in HEK-293T. (e) RanBP6 KD increases activation of the EGFR downstream 882 
signaling pathways and does not impair EGF-induced EGFR degradation in HEK-293T cells. 883 
Upper panel, immunoblot of whole cell lysates serum starved for 16h and then stimulated with 884 
EGF (100ng/ml) for the indicated time points; Lower panel, densitometric analysis of EGFR. 885 
Data in bar graphs are represented as mean ± SD (n>=3). Student’s t test: ***P < 0.001; **P < 886 
0.01; ns, not significant.   887 
Figure 3. RanBP6 promotes nuclear translocation of STAT3  888 
(a) RANBP6 KO increases cytoplasmic STAT3 and lowers nuclear STAT3. Left panel, 889 
immunoblots of cytoplasmic (Cyt.) and nuclear (Nuc.) cell fractions; right panel, densitometry of 890 
STAT3 immunoblots. (b) RanBP6 KD impairs IL-6 induced nuclear STAT3 translocation. Left 891 
panel, confocal immunofluorescence. RFP is used as a reporter for shRNA expression. Right 892 
panel, ratios of nuclear/cytoplasmic STAT3 staining (Field of views: Vehicle, n=18; Ruxolitinib, 893 
n=13; RANBP6-shRNA, n=21). The Janus kinase (JAK) inhibitor ruxolitinib was included as a 894 
positive control. Scale bar = 10μm (c) RanBP6 KD decreases transcription of STAT3 reporter 895 
gene. SIE= sis-inducible elements. (d) Gene expression profiling showing the effect of RanBP6 896 
KD on endogenous STAT3 target genes. Heatmap represents the enrichment scores from single 897 
sample gene set enrichment analysis (ssGSEA) of three biological replicates. Student’s t test p-898 
values (Dox- versus Dox+) for each gene sets are indicated. (e) Quantitative PCR analysis of the 899 
expression of some RanBP6 regulated genes selected from ssGSEA (top panel) confirmed to be 900 
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regulated by STAT3 (bottom panel). Data are represented as mean ± SD (n>=3). Student’s t test: 901 
***P < 0.001; **P < 0.01; ns, not significant.  902 
 903 
Figure 4. STAT3 represses EGFR transcription  904 
(a) STAT3 KD raises EGFR mRNA (left panel) and EGFR protein levels (right panel) in HEK-905 
293T. (b) STAT3 binding to the EGFR promoter is impaired by RanBP6 KD. Bottom panel, 906 
ChIP experiments on the promoter of indicated genes with STAT3 antibody in LN18 cells with 907 
Dox –inducible shRanBP6. Plotted values are relative enrichments to % input, measured for two 908 
regions (EGFR_1 and EGFR_2) in 1.5kb upstream of EGFR transcriptional start site (TSS) (see 909 
top panel). Binding to the PTGS2 and HPRT promoter were used as positive and negative 910 
control, respectively. (c) STAT3 and p-STAT3 (Y-705) bind GST-RanBP6 fusion protein in 911 
HEK-293T whole cell lysates. (d) Expression of a constitutive active STAT3 mutant decreases 912 
EGFR mRNA (left panel) and EGFR protein levels (right panel) in HEK-293T. (e) Inhibition of 913 
STAT3 activation by JAK kinase inhibitor ruxolitinib raised EGFR protein level in HEK293T. 914 
(f) JAK-STAT blockage with ruxolitinib mitigates the effect of RanBP6 KD on EGFR protein 915 
levels in HEK-293T. Right panel, densitometric analysis of EGFR ratio between Dox+ and Dox– 916 
samples for each treatment. Data in bar graphs are represented as mean ± SD (n>=3). Student’s t 917 
test: ***P < 0.001; **P < 0.01; ns, not significant.   918 
Figure 5. EGFR regulation by RanBP6 is disrupted in PTEN-deficient cells  919 
(a) Co-immunoprecipitation of EGFR and V5 epitope tagged RanBP6-V5 in A431 cells serum 920 
starved and induced with EGF (100ng/ml) for 5 minutes. Top panel, IP using V5 antibody; 921 
bottom panel, immunoblot of whole cell lysates (WCL). (b) Interaction of GST-RanBP6 fusion 922 
protein with EGFR is Akt dependent. Left panel, GST pull-down; right lower panel, 923 
densitometric quantification of GST pull-down; right upper panel, immunoblot of whole cell 924 
lysate. (c) PTEN loss disrupts interaction of GST-RanBP6 fusion protein with EGFR. Left panel, 925 
GST-RanBP6 fusion protein interacts with EGFR in PTENlox/lox but not PTENΔ/Δ MEFs; Right 926 
panel, immunoblot of whole cell lysates. (d) RanBP6 KD raises EGFR mRNA level in 927 
PTENlox/lox but not PTENΔ/Δ MEFs. Left panel, EGFR mRNA level; middle panel, RanBP6 928 
mRNA level; right panel, PTEN mRNA level. (e) Left panel, negative correlation between 929 
RANBP6 and EGFR mRNA Z-score in the Cancer Cell Line Encyclopedia (n = 877, Pearson 930 
product-moment correlation r = −0.203, p value = 1e−09). Right panels, cancer cell lines were 931 
stratified accordingly to PTEN status. Inverse correlation between RANBP6 and EGFR mRNA 932 
levels only in PTEN-intact cancer cell lines (n = 734, Pearson product-moment correlation r = 933 
−0.22, p value = 2e−09) but not PTEN altered cell lines (n = 143, Pearson product-moment 934 
correlation r = −0.066, p value = 0.43). Data in bar graphs are represented as mean ± SD (n>=3). 935 
Student’s t test: ***P < 0.001; ns, not significant.   936 
 937 
Figure 6. RanBP6 suppresses growth factor output and glioma growth 938 
(a) Focal deletions of the RANBP6 (left) and CDKN2A (right) in GBM. (b) Relationship 939 
between RANBP6 copy number and mRNA levels in GBM (n = 151); Tukey's Honest 940 
Significant Difference: ***P < 0.001. (c) RanBP6 protein levels in a panel of established patient-941 
derived GBM tumor spheres. Shown are immunoblots of whole cell lysates. (d) Ectopic 942 
expression of RanBP6-V5 in RanBP6-low TS516 GBM neurosphere reduces anchorage-943 
independent growth. (e) Ectopic expression of RanBP6-V5 reduces EGFR protein levels in a 944 
time-dependent manner. (f) RanBP6 overexpression reduces tumor growth (left panel) and 945 
EGFR expression in a TS516 xenograft model (right panel). Student’s t test: *P < 0.05. (g) 946 
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RanBP6 KD reduces survival in RCAS-tva mouse glioma model. Kaplan Meier survival curves 947 
of PDGFB-induced gliomas generated in Nestin-tva mice injected with either RCAS-RanBP6 948 
shRNA or RCAS-Luciferase shRNA as a control. (h) Tumor grade (WHO classification) of 949 
gliomas in the RCAS-tva model. (i) RanBP6 KD increases EGFR mRNA in samples from the 950 
RCAS-tva mice. Data in bar graphs are represented as mean ± SD (n>=3). 951 
 952 
Figure 7. EGFR regulation by RanBP6 (model). A (small) pool of EGF receptors functions as 953 
a scaffold for RanBP6-mediated nuclear import of STAT3. Nuclear STAT3 represses EGFR 954 
transcription. The solid lines between EGFR-STAT3-RanBP6 and RanBP6-Ran indicate protein-955 
protein interactions (i.e., not necessarily direct molecular interactions). This mechanism of 956 
EGFR regulation serves to repress EGFR transcription at steady-state and is inactivated when the 957 
cellular demand for EGFR transcription increases (for example, following EGF-induced receptor 958 
protein degradation). Cancer cells inactivate this physiologic mechanism of EGFR regulation 959 
through deletion of the RanBP6 gene or silencing of PTEN (which disrupts the EGFR-RanBP6 960 
interactions).   961 
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